Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up
LG

LGND

Market Closed

Ligand Pharmaceuticals Incorporated

NASDAQHealthcareBiotechnology
US
47 employees
CEO: Todd C. Davis
Founded: 1992
$280.87
+$0.00(+NaN%)
Market Cap
5.63B
Beta
0.98
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Based on PERT weighted analysis (confidence: high), the fair value is $623.62, implying 123.1% upside from current levels. The stock appears significantly undervalued. Financial health scores indicate strong fundamentals (4.2/5). Monte Carlo analysis shows high downside risk (100% of scenarios below current price). Overall, this suggests a compelling buying opportunity at current prices.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore LGND

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

LGND in the Healthcare

Mid Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms